EA202192757A1 - Способ лечения опухолей - Google Patents
Способ лечения опухолейInfo
- Publication number
- EA202192757A1 EA202192757A1 EA202192757A EA202192757A EA202192757A1 EA 202192757 A1 EA202192757 A1 EA 202192757A1 EA 202192757 A EA202192757 A EA 202192757A EA 202192757 A EA202192757 A EA 202192757A EA 202192757 A1 EA202192757 A1 EA 202192757A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tumor treatment
- effect
- tumors
- epoxytiglienone
- abscopal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к способам лечения опухолей, включающим локализованное введение, например внутриопухолево или местно, соединения эпокситиглиенона (в качестве монотерапии) в раковые опухоли для генерирования системного противоракового абскопального (аненестического) эффекта и/или эффекта "свидетеля".
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019901280A AU2019901280A0 (en) | 2019-04-12 | Method of Treatment | |
PCT/AU2020/050360 WO2020206504A1 (en) | 2019-04-12 | 2020-04-09 | Method of treating tumours |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192757A1 true EA202192757A1 (ru) | 2022-02-11 |
Family
ID=72752169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192757A EA202192757A1 (ru) | 2019-04-12 | 2020-04-09 | Способ лечения опухолей |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220193023A1 (ru) |
EP (1) | EP3952858A4 (ru) |
JP (1) | JP2022528915A (ru) |
KR (1) | KR20210152531A (ru) |
CN (1) | CN113924091A (ru) |
AU (1) | AU2020256847A1 (ru) |
BR (1) | BR112021020253A2 (ru) |
CA (1) | CA3136216C (ru) |
EA (1) | EA202192757A1 (ru) |
IL (1) | IL287210A (ru) |
MX (1) | MX2021012449A (ru) |
SG (1) | SG11202110599RA (ru) |
WO (1) | WO2020206504A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1971588T3 (da) * | 2005-12-23 | 2012-10-22 | Qbiotics Ltd | Tiglien-3-onderivater |
WO2023115123A1 (en) * | 2021-12-21 | 2023-06-29 | QBiotics Pty Ltd | Crystalline intermediates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1971588T3 (da) * | 2005-12-23 | 2012-10-22 | Qbiotics Ltd | Tiglien-3-onderivater |
LT2986615T (lt) | 2013-04-18 | 2019-03-25 | Qbiotics Limited | Būdai ir kompozicijos, skirti žmogaus žaizdų gydymui |
BR112019001365A2 (pt) * | 2016-07-28 | 2019-04-30 | Qbiotics Limited | método de tratamento |
EA201992220A1 (ru) * | 2017-03-23 | 2020-02-11 | Кьюбиотикс Пти Лтд | Комбинированная терапия для лечения или предупреждения опухолей |
-
2020
- 2020-04-09 EA EA202192757A patent/EA202192757A1/ru unknown
- 2020-04-09 BR BR112021020253A patent/BR112021020253A2/pt unknown
- 2020-04-09 MX MX2021012449A patent/MX2021012449A/es unknown
- 2020-04-09 SG SG11202110599RA patent/SG11202110599RA/en unknown
- 2020-04-09 EP EP20787143.5A patent/EP3952858A4/en active Pending
- 2020-04-09 AU AU2020256847A patent/AU2020256847A1/en active Pending
- 2020-04-09 US US17/602,909 patent/US20220193023A1/en active Pending
- 2020-04-09 CN CN202080042217.2A patent/CN113924091A/zh active Pending
- 2020-04-09 KR KR1020217036942A patent/KR20210152531A/ko active Search and Examination
- 2020-04-09 CA CA3136216A patent/CA3136216C/en active Active
- 2020-04-09 JP JP2021559659A patent/JP2022528915A/ja active Pending
- 2020-04-09 WO PCT/AU2020/050360 patent/WO2020206504A1/en active Search and Examination
-
2021
- 2021-10-12 IL IL287210A patent/IL287210A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020206504A1 (en) | 2020-10-15 |
AU2020256847A1 (en) | 2021-11-11 |
CA3136216C (en) | 2024-01-16 |
SG11202110599RA (en) | 2021-10-28 |
US20220193023A1 (en) | 2022-06-23 |
EP3952858A1 (en) | 2022-02-16 |
CA3136216A1 (en) | 2020-10-15 |
IL287210A (en) | 2021-12-01 |
KR20210152531A (ko) | 2021-12-15 |
BR112021020253A2 (pt) | 2021-12-07 |
MX2021012449A (es) | 2021-11-12 |
JP2022528915A (ja) | 2022-06-16 |
EP3952858A4 (en) | 2022-05-25 |
CN113924091A (zh) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
PH12019501896A1 (en) | Therapeutic dendrimers | |
RU2012140185A (ru) | Ингибирование ангиогенеза | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
TW201613589A (en) | Combination methods for treating cancers | |
CY1125126T1 (el) | Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης | |
EA202092540A1 (ru) | Комбинации для лечения рака | |
EA202190403A1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
EA202192757A1 (ru) | Способ лечения опухолей | |
JOP20200244A1 (ar) | مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
MX2021014226A (es) | Arn terapeutico para cancer de ovario. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
EA202092861A1 (ru) | Специфичные в отношении злокачественной опухоли t-клеточные рецепторы | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
EA202190457A1 (ru) | Конъюгаты для применения в способах лечения рака |